DANIEL RUDMAN, M.D.; RAJENDER K. CHAWLA, Ph.D.; STEVEN B. HEYMSFIELD, M.D.; ROBERT A. BETHEL, M.D.; MAMORU SHOJI, M.D.; W. RALPH VOGLER, M.D.; DANIEL W. NIXON, M.D.
RUDMAN D, CHAWLA RK, HEYMSFIELD SB, BETHEL RA, SHOJI M, VOGLER WR, et al. Urinary Excretion of the Cancer-Related Glycoprotein EDCI: Effect of Chemotherapy. Ann Intern Med. 1977;86:174-179. doi: 10.7326/0003-4819-86-2-174
Download citation file:
Published: Ann Intern Med. 1977;86(2):174-179.
The effect of chemotherapy on the urinary excretion of a cancer-related glycoprotein labeled EDCI, recently isolated from the urine of a patient with acute myelocytic leukemia, has been studied by radioimmunoassay in eight cancer patients who were excreting 200 to 500 mg/day before treatment. In five patients, chemotherapy caused marked clinical improvement, and the glycoprotein disappeared from the urine within 10 days after chemotherapy began. In the two patients with solid tumor who responded to chemotherapy, disappearance of glycoprotein EDCI from the urine preceded clinical improvement by 1 to 2 months. Four of the five responsive patients relapsed within 6 months; in each instance, the glycoprotein reappeared in the urine (> 100 mg/day) 2 to 5 weeks before clinical relapse. Three patients were resistant to chemotherapy, and their urinary glycoprotein did not decline during chemotherapy. Measurement of urinary glycoprotein EDCI will be useful in rapidly ascertaining which drug will be effective in a cancer patient and in predicting relapse.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only